Anzeige
Mehr »
Samstag, 16.05.2026 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40DEH | ISIN: US09073Q3039 | Ticker-Symbol: 2F5
Tradegate
15.05.26 | 08:29
0,450 Euro
-2,60 % -0,012
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
SCINAI IMMUNOTHERAPEUTICS LTD ADR Chart 1 Jahr
5-Tage-Chart
SCINAI IMMUNOTHERAPEUTICS LTD ADR 5-Tage-Chart
RealtimeGeldBriefZeit
0,4460,46215.05.
0,4500,47415.05.

Aktuelle News zur SCINAI IMMUNOTHERAPEUTICS LTD Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
08.05.Scinai Immunotherapeutics Ltd. - 6-K, Report of foreign issuer-
24.04.Scinai raises $2.61M in private placement to expand CDMO unit13
24.04.Scinai ImmunoTherapeutics skyrockets premarket on $2.61M private placement financing5
06.04.Scinai Completes Corporate Reorganization Separating CDMO and R&D Operations8
06.04.Scinai schließt Unternehmensumstrukturierung ab und gliedert CDMO-Einheit aus13
06.04.Scinai completes corporate reorganization, separates CDMO unit3
SCINAI IMMUNOTHERAPEUTICS LTD Aktie jetzt für 0€ handeln
06.04.SCINAI IMMUNOTHERAPEUTICS LTD: Scinai Completes Strategic Reorganization to Establish Dedicated CDMO Platform and Lean R&D Structure; Outlines 2026 Priorities749JERUSALEM, April 6, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI); ("Scinai" or the "Company"), a biopharmaceutical company developing inflammation...
► Artikel lesen
02.04.Scinai ImmunoTherapeutics reports FY results3
01.04.Scinai Immunotherapeutics Ltd.: Scinai Reports Full-Year 2025 Results, with CDMO Revenues Doubling and Strategic Expansion Through Recipharm Collaboration270JERUSALEM, April 1, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI); ("Scinai" or the "Company"), a biopharmaceutical company operating a dual...
► Artikel lesen
01.04.Scinai Immunotherapeutics Ltd. - 20-F, Annual and transition report of foreign private issuers1
19.03.Scinai Immunotherapeutics Ltd. - 6-K, Report of foreign issuer1
16.03.Scinai Immunotherapeutics Ltd.: Scinai Immunotherapeutics Receives Nasdaq Notification Regarding Minimum Bid Price280JERUSALEM, March 16, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai" or the "Company"), today announced that it received a written...
► Artikel lesen
16.03.Scinai ImmunoTherapeutics receives Nasdaq notice over minimum bid price requirement1
25.02.Scinai Immunotherapeutics Ltd. - 6-K, Report of foreign issuer14
25.02.Scinai receives expanded grant for robotic manufacturing system3
17.02.Scinai Immunotherapeutics Buys Recipharm Israel2
17.02.Scinai Immunotherapeutics Ltd. - 6-K, Report of foreign issuer1
17.02.Scinai Immunotherapeutics Ltd.: Scinai Announces Completion of Acquisition of Recipharm Israel Ltd. and Strategic Commercial Collaboration with Recipharm248JERUSALEM, Feb. 17, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company developing inflammation and immunology...
► Artikel lesen
23.12.25Scinai Immunotherapeutics Ltd. - 6-K, Report of foreign issuer-
02.12.25Scinai Immunotherapeutics Ltd. - 6-K, Report of foreign issuer2
Weiter >>
25 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1